Development of a National Minimal
• The aim is to develop and evaluate new solutions for value-based diabetes care in Denmark under the heading: Improving care by focusing on what matters most to people with diabetes (PwD).
• A key objective is to enable coordinated cross-sectorial and multidisciplinary action to improve care through a clinical and analytical solution designed around a shared definition of "patient value".
• The first step presented here was to establish a minimal set of patient-important outcome domains, incl. PRO, to asses "value".
Background Value based care projects in Denmark
• Decided by the Board of Danish Regions and part of the Financial Agreement from 2016.
• Northern Denmark Region is appointed regional lead on value based diabetes care.
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Aims of the qualitative research
• Inform selection of a minimal set of patient-important diabetes outcome domains for VHBC by the national multisectorial and multi-disciplinary working group (incl. PwD).
• Using the VBHC framework (Porter et al 2010) , specific aims was to gain perspective of PwD and caregivers on: 
Method (1) Qualitative methodology
• Qualitative research as part of evidence-guided quality patient engagement (PFMD, NIH 2018) using 7 criteria: Shared purpose, respect, responsibility, representativeness, capacity/capability, documentation and sustainability.
• Individual semi-structured interviews and workshops were undertaken with 24 persons with diabetes and caregivers.
• Recruitment was done by a diabetes nurse at the University Hospital in collaboration with the local diabetes organization.
• An analytical selection process was applied to 1) maximize variation and 2) apply theory-driven qualitative selection for representativeness
Method (2) Qualitative methodology
Semi structured interviews:
• Participants completed open-ended questions individually.
For example: -"The most important ways my diabetes affects my [physical health] / [social and psychological wellbeing] is…….." -"My treatment is succesful when I…….." -"The most important way diabetes affects my life as a caregiver is……."
Focus group and workshops:
• A 4 hour highly structured patient workshop consisting of focus group, consensus and co-creation sessions (see agenda below).
Qualitative analysis:
• Individual responses and group process outputs were analysed and coded separately.
• Outputs were combined in final report taking into account group dynamics, differences and analyses of coherence.
• 4 caregivers were included for hypothesis generating purposes. The results for caregivers will be presented elsewhere.
Agenda overview. 4 hour workshop
Introduction and welcome by local patient organisation head and investigator.
Group discussion sessions I. 
Results (2) Key observations
PwD and caregivers found the following of high importance for evaluation of achieved health outcomes in VBHC context:
• Blood sugar control (A1c, BGM, CGM), clinical risk factors for late stage complications, hospitalization, ketoacidosis.
• Emotional diabetes distress, impact on quality of life, burden of treatment (medication, injection, testing, lifestyle), well/being
• Key to also assess quality of care and confidence in self-care
Group level analyses further highlighted
• Outcome domains supported by individual and group-based data • Main outcome domain differentiation was related to treatment modality (insulin/pump) and burden of complications.
• Every person has unique individual goals that shift over time. Huge heterogeneity in needs/priorities across the lifespan.
Results (3) Thematic analysis (goals)

VBHC tier Qualitative outcomes (PwD goals) by VBHC tiers
Achieved or desired health status
Be able to live as normal a life as possible. (Avoiding negative impacts on physical health, emotional, work, social, family, leisure life, lifestyle).
Achieve good blood sugar control (A1c) to stay healthy and prevent complications. Staying "in range" using BGM and CGM measurements. Minimise risk of health problems and late stage complications.
Maintain psychological wellbeing, avoid depression and emotional distress (avoiding constant fear of future complications, feeling alone, feeling that diabetes interferes in social life) Get attention to and care for full range of diabetes related somatic symptom distress, such as pain (neuropathic), erectile dysfunction, diabetes related sleep problems, tiredness (hyperglycemia).
Disutilities of treatment
Minimise burden and interference of diabetes treatment in daily life (social, family, mood, work, etc). Make treatment easier, more convenient. Reduce daily frustrations and need for constant attention.
Avoid risk of and fear of mild, moderate and severe hypoglycemia. Minimise the emotional, mental, physical and behavioral consequences of hypoglycemia or the fear of hypoglycemia.
Gastrointestinal and other side effects of diabetes medications.
Sustainability factors
Have confidence, sense of security in care, reliable technology, qualified coordinated ongoing support, be treated as a "whole person", involved as partner, helped to navigate healthcare and community resources, mobilise social support and motivation, support from surroundings for diabetes.
Feel able, informed and equipped to master and manage own diabetes care. Feel confident with own understanding, competence and motivation to take care of own diabetes while living a good life. 
Results (4) PRO outcome domains
Conclusions and next steps
• Qualitative research and partnering with PwD informed national multi-stakeholder expert decision process regarding relevance of PRO-based outcome domains for outcomes assessment in value based diabetes care.
• Domains were supported by follow-up patient workshops, survey research in collaboration with ICHOM, and by literature review of multi-national qualitative and survey research (Nicolucci, Stucky, Young-Hyman).
• Next phases now are to further detail domains, finalise national PRO questionnaires, develop and test final VHBC PRO diabetes care solution in Northern Region of Denmark and with collaborating regions/sites.
• Our research supports use of our clinically anchored evidence-guided PwD partnering process for all steps of PRO implementation, including item selection, linking PRO to care actions and considering vulnerable groups.
• PRO item bank and branching technology is applied to address population heterogeneity and cross-sectorial use.
• International collaboration for harmonisation of PRO diabetes methods is helpful to future national PRO efforts.
